This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, PK, and immunogenicity of multiple subcutaneous doses of TRIV-509 in participants 18 to
75 years of age with moderate to severe AD.
Volunteers needed for up to a 57-week-long clinical trial with up to 14 office visits for an investigational product. Stipend up to $1980 if eligible.
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 18-75 years of age.
2.) Have moderate to severe eczema (atopic dermatitis).
3.) Must weigh more than 88.2 lbs.
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) History of cancer or lymphoproliferative disease within the last 5 years.
2.) Test positive for HIV.
3.) Be pregnant or plan on becoming pregnant.
ClinicalTrials.gov ID NCT07167758
We love our patients, so feel free to visit during normal business hours.
510 S Cowley Spokane, WA 99202
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.